Is ISRG a Buy? What to Consider in 2026
Short answer
There is no universal answer to whether ISRG is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for Intuitive Surgical, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.
Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California. It is the clear leader in surgical robotics with a wide moat, strong margins, and consistent procedure-volume growth, though it trades at a premium valuation that reflects those qualities.
What's the case for buying ISRG?
1. Razor-and-blade recurring revenue.
Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. As the installed base and procedure volumes grow, this recurring stream compounds with high margins and far more predictability than one-time capital sales.
2. Installed base and switching costs.
Hospitals invest heavily in da Vinci systems, surgeon training, and workflow integration, which creates strong switching costs and a durable relationship. A growing global installed base of systems expands the addressable procedure pool each year and gives Intuitive a platform to introduce new procedures and instruments.
3. Platform expansion and new procedures.
Newer systems like da Vinci 5 and the Ion robotic bronchoscopy platform for lung biopsy extend Intuitive's reach into additional specialties. Each newly validated procedure type and geographic expansion broadens the runway for procedure growth, supported by clinical evidence and surgeon adoption.
What are the risks to ISRG?
ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Competition is intensifying as Medtronic, Johnson & Johnson, and others develop rival surgical-robotics platforms that could erode Intuitive's dominance over time. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps.
How is ISRG valued? (as of early 2026)
- Revenue (TTM): ~$8 to 9 billion (verify)
- Recurring revenue share: ~80%+ from instruments, accessories, and service
- Operating margin: ~30% (strong)
- Gross margin: ~65% to 68%
- P/E (TTM): ~60x to 75x (premium; verify)
- Dividend: Initiated a modest dividend recently (verify status and yield)
- Procedure growth: High-single to low-double-digit annual growth
- Balance sheet: Strong; large net cash position
Intuitive trades at a high earnings multiple that reflects its dominant market position, high-margin recurring revenue, strong balance sheet, and consistent procedure-volume growth. The premium is the central debate: bulls justify it with the durability of the razor-and-blade model and a long runway, while bears point to multiple-compression risk if procedure growth slows or competitors gain share. Figures are approximate and should be verified against the latest filing.
How do you decide if ISRG is a buy?
Rather than asking whether ISRG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ISRG indirectly through an index or sector ETF before adding more.
For the full picture, see the ISRG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ISRG against your real portfolio and see your actual exposure before deciding.
The bottom line on ISRG
Whether ISRG is a buy is not a universal verdict; it comes down to your thesis, your time horizon, and what you already own. Intuitive Surgical has a real case (above) and real risks to weigh. If you believe the thesis, the questions that matter are position sizing and overlap, not market timing. Walnut can show how ISRG sits against your actual holdings before you decide. It is not an investment adviser.
Build a basket around ISRG with Walnut
Use Intuitive Surgical as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ISRG a good stock to buy right now?
+
There is no universal answer. Whether Intuitive Surgical fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.
What does Intuitive Surgical do?
+
Dominant surgical-robotics maker (da Vinci), with a razor-and-blade model where instrument and service revenue compounds with procedure volume.
What are the main risks of ISRG?
+
ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Competition is intensifying as Medtronic, Johnson & Johnson, and others develop rival surgical-robotics platforms that could erode Intuitive's dominance over time. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps.
What is Intuitive Surgical's ticker symbol?
+
ISRG, listed on Nasdaq. The company is Intuitive Surgical, Inc., headquartered in Sunnyvale, California. It went public in 2000 and trades during US market hours at every major US brokerage.
What does Intuitive Surgical do?
+
Intuitive Surgical makes robotic-assisted surgery systems, most notably the da Vinci platform used for minimally invasive procedures in urology, gynecology, general surgery, and other specialties. It also makes the Ion platform for robotic lung biopsy. It earns most revenue from single-use instruments, accessories, and service, not just system sales.
Why is ISRG considered a high-quality stock?
+
Intuitive has a razor-and-blade model where recurring, high-margin revenue from instruments and service grows with procedure volume on a large installed base. High switching costs, strong margins, a clean balance sheet, and consistent procedure growth give it a wide moat that investors value highly.
Who are Intuitive Surgical's competitors?
+
In surgical robotics, Medtronic (Hugo) and Johnson & Johnson (Ottava) are developing rival systems. Traditional laparoscopic instruments from Medtronic and J&J's Ethicon compete where robotics is not used. In robotic bronchoscopy, Intuitive's Ion competes with platforms like J&J's Monarch.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ISRG; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.